Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)

LOS ANGELES–()–ChromaDex Corp. (NASDAQ:CDXC) at this time introduced that Sinopharm Xingsha will debut Tru Niagen® on the main mainland China commerce present, China International Natural Health & Nutrition Expo (NHNE), which kicks off Tuesday, September 20, in Shanghai. NHNE is Asia’s largest expo on pure well being and vitamin merchandise, with over 100,000 distributors and retailers. It’s thought-about one of the best platform to assist world producers of well being meals and vitamin promote their manufacturers and broaden enterprise channels in China, the place Tru Niagen® is at the moment bought cross-border.

Niagen®, the proprietary ingredient in Tru Niagen®, is the world’s most effective, patent protected nicotinamide adenine dinucleotide (NAD+) precursor in the marketplace, notably over NMN, and is likely one of the most promising components to have entered the wholesome getting old complement house. Supplementation with Niagen® is backed by 20 revealed and peer-reviewed scientific trials, backed by over 200 revealed scientific research and has over 30 owned and licensed patents.

“China’s market stays strategically vital as customers already perceive the advantages of elevating NAD+ and it’s our intention to change into the main supplier of NAD+ boosting dietary supplements available in the market,” mentioned Rob Fried, CEO of ChromaDex. “NHNE presents the proper platform to achieve a various community of distributors and retailers to broaden Tru Niagen® cross-border gross sales as we work towards attaining Blue Hat approval available in the market with Sinopharm Xingsha. We’re grateful to Sinopharm Xingsha for main the debut of Tru Niagen® at NHNE.”

Along with receiving prime actual property in Sinopharm Xingsha’s 162 meter sales space on the exhibition web site, Tru Niagen® will host a celebratory press convention that includes a video of ChromaDex CEO, Rob Fried, following the NHNE opening ceremony. Tru Niagen® will even obtain the ‘Most In style Model of the Yr’ award through the High 100 Awards Ceremony on the expo’s celebratory Diet Planet Dinner.

“It’s been a pleasure to work with ChromaDex as we construct upon our development technique for Tru Niagen® in China and our group is thrilled to debut Tru Niagen® at NHNE this week,” mentioned Pan Lei, Basic Supervisor of Sinopharm Xingsha. “We’ll use our profitable expertise in model promotion and channel building within the Chinese language market to raise Tru Niagen® and broaden product gross sales in China. Concurrently, we stay up for leveraging ChromaDex’s experience in science, R&D and manufacturing to affect the trade in China and lift consciousness across the impactful analysis behind Tru Niagen®.”

Tru Niagen® is at the moment out there on the market to Chinese language customers on a number of cross-border on-line and market platforms, primarily by T-mall, and JD, with future enlargement being led by Sinopharm Xingsha. Tru Niagen® can be out there in over 200 Watsons shops in Hong Kong and Macau, in addition to over 100 Watsons shops in Singapore.

Niagen® has achieved regulatory acceptance to be used in dietary supplements by the US FDA. Moreover, Niagen® has been authorised to be used in meals dietary supplements by the European Fee, complementary medicines by the Therapeutic Items Administration of Australia (TGA), medical meals by the Brazilian Well being Regulatory Company (ANVISA), and medical meals by the Meals Requirements Australia New Zealand (FSANZ). Tru Niagen® has additionally been authorised by Well being Canada as a Pure Well being Product. ChromaDex continues to steer the trade in NAD+ analysis, with the ChromaDex Exterior Analysis Program (CERP) celebrating over 250 materials switch agreements (MTAs) that includes Niagen® and different proprietary components.

For extra data on ChromaDex, go to www.chromadex.com and for extra data on the NHNE convention, please go to ChromaDex’s WeChat profile.

About ChromaDex:

ChromaDex Corp. is a world bioscience firm devoted to wholesome getting old. The ChromaDex group, which incorporates world-renowned scientists, is pioneering analysis on nicotinamide adenine dinucleotide (NAD+), ranges of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized because the flagship ingredient Niagen®. Nicotinamide riboside and different NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a web site at www.chromadex.com to which ChromaDex commonly posts copies of its press releases in addition to extra and monetary details about the Firm.

Ahead-Trying Statements:

This launch comprises forward-looking statements throughout the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities and Trade Act of 1934, as amended, together with statements associated to Tru Niagen® being some of the promising components to have entered the wholesome getting old complement house in China’s market, its strategic significance, and customers understanding of the advantages of elevating NAD+. Statements that aren’t an outline of historic info represent forward-looking statements and should usually, however not at all times, be recognized by way of such phrases as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “potential,” “possible,” “believes,” “seeks,” “might,” “will,” “ought to,” “may” or the destructive of such phrases or different comparable expressions. Dangers that contribute to the unsure nature of those forward-looking statements embrace the impression of the COVID-19 pandemic on our enterprise and the worldwide economic system; our historical past of working losses and have to receive extra financing; the expansion and profitability of our product gross sales; our means to take care of gross sales, advertising and distribution capabilities; altering client perceptions of our merchandise; our reliance on a single or restricted variety of third-party suppliers; and the dangers and uncertainties related to our enterprise and monetary situation. Extra detailed details about ChromaDex and the danger elements which will have an effect on the conclusion of forward-looking statements is ready forth in ChromaDex’s Annual Report on Kind 10-Okay for the fiscal yr ended December 31, 2021, ChromaDex’s Quarterly Studies on Kind 10-Q and different filings submitted by ChromaDex to the SEC, copies of which can be obtained from the SEC’s web site at www.sec.gov. Readers are cautioned to not place undue reliance on these forward-looking statements, which converse solely as of the date hereof, and precise outcomes might differ materially from these instructed by these forward-looking statements. All forward-looking statements are certified of their entirety by this cautionary assertion and ChromaDex undertakes no obligation to revise or replace this launch to replicate occasions or circumstances after the date hereof.

Comments

0 comments

Leave a comment

Your email address will not be published. Required fields are marked *